Fulgent Genetics Inc. sprung into action when Covid-19 hit. Fulgent delivers 95% of results within 24 hours of samples arriving at our lab. Non-GAAP income (loss) and adjusted EBITDA are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables. About Fulgent Genetics. Press and industry analysts are invited to attend in listen-only mode. Alameda County community testing sites are free. While the majority of our testing volume this quarter comprised of COVID-19 tests, our core genetic testing business rebounded nicely and grew 57% sequentially from the second quarter. The non-GAAP tax effect is calculated by applying statutory corporate tax rate on GAAP income (loss) before equity-based compensation expenses, provisions (benefits) for income taxes, equity income (loss) in investee and impairment loss in equity-method investment. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 1466548 through November 16, 2020. You will not be asked about your immigration status. For the three-month period ended June 30, Fulgent’s revenues rose to $8.4 million USD, up from $5.4 million USD for the same period last year. Read about the company's swift help in providing Covid-19 testing during the pandemic … Fulgent Genetics had a net margin of 5.78% and a return on equity of 5.05%. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. 30, 2020. Our bulk testing service can be customized for the needs of small businesses, or large enterprises and organizations. The company’s stock price has collected -1.47% of loss in the last five trading sessions. Fulgent Genetics believes this information is useful to investors because it provides a basis for measuring the performance of Fulgent’s business excluding certain income or expense items that management believes are not directly attributable to the company’s core operating results. We expect to see continued momentum across our business in the fourth quarter, and are pleased to be raising our revenue guidance for the full year. 2018 © Fulgent Genetics. Fulgent Genetics defines adjusted EBITDA as GAAP income (loss) plus or minus interest expense (income), plus or minus provisions (benefits) for income taxes, plus depreciation, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, plus impairment loss in equity-method investment, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. Anyone who lives or works in Orange County can now get tested for COVID-19 at the Orange County COVID-19 Testing Super Site locations. Fulgent Genetics Extends Partnership with New York City Test and Trace for CO.. Insider at Fulgent Genetics (FLGT) Makes Significant Sale of Stock. Press and … Our recent momentum is a result of the investments we have made in our business and technology platform over many years. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its first quarter 2020 results. This growth was made possible by our capacity and laboratory expansion, including the opening of our new laboratory in Houston, coupled with our highly efficient testing and reporting systems that we worked to develop over the years. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its second quarter 2020 results. Fever or chills It is understandable that investor optimism is growing ahead of the company’s current quarter results. Fulgent Genetics (NASDAQ:FLGT) issued its quarterly earnings data on Monday. TEMPLE CITY, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced financial results for its … By using our website and agreeing to our Cookie Policy, you consent to our use of cookies. Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million PRESS RELEASE GlobeNewswire Nov. 9, 2020, 10:05 PM Item 2.02 Results of Operations and Financial Condition. Testing is currently available on an as-needed basis for all Ventura County residents. You will not be asked about your immigration status. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its first quarter 2020 results. ii Testing is currently available to all Alameda County residents. Fulgent Genetics believes this information is useful to investors because it provides a basis for measuring the performance of the company’s business excluding certain income or expense items that management believes are not directly attributable to the company’s core operating results. Accept Testing is currently available to all Alameda County residents. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent Genetics may not be comparable to similarly titled metrics reported by other companies. According to James Xie, Chief Operating Officer, Fulgent Genetics, "Fulgent Genetics is committed to delivering up-to-the-minute COVID-19 test results … These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release. Fulgent Genetics updated its Q4 2020 After-Hours guidance to […] Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its fourth quarter and full year 2019 results… Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its second quarter 2020 results. We expect to continue investing in our platform to expand our capabilities as we look to capture share in the broader genetic testing market in the future. ... a new line of at-home screening tests that combines the company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 1466548. Adjusted EBITDA was $67.4 million in the third quarter of 2020, compared to $3.0 million in the third quarter of 2019. The Company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. All rights reserved. The company’s reports filed with the U.S. Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the SEC. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its third quarter 2020 results. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemic’s effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the company’s tests, including its newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. Fulgent Genetics Inc. (NASDAQ:FLGT) went up by 8.01% from its latest closing price compared to the recent 1-year high of $79.64. TEMPLE CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced financial results for its second quarter ended June 30, 2019. LANES, Fulgent Genetics and LA County Department of Health Services Collaborate to Fast-Track COVID-19 Test Results to Local Healthcare Providers PRESS RELEASE PR … Ming Hsieh, Chairman and Chief Executive Officer, said, “I am very pleased with our outstanding third quarter results, which demonstrate the true scalability of our technology platform for genetic testing. A copy of the Company's press release containing this information is TEMPLE CITY, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2020 financial results after the market closes on Monday November 9, 2020. Most test results are available within 48-72 hours. Alameda County community testing sites are free. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its third quarter results. The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Who pays for my test? In particular, you are encouraged to review the company’s quarterly report on Form 10-Q for the quarter ended September 30, 2020 for any revisions or updates to the information in this release. --Fulgent Genetics, a provider of comprehensive genetic testing and Next Generation Sequencing solutions, today announced financial results for … Investor Relations Contact:The Blueshirt GroupNicole Borsje, 415-217-2633, nicole@blueshirtgroup.com, Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million. Chromosomal Sequencing Analysis (CSA) Form, Accounts payable, accrued liabilities and other liabilities, Income before income taxes, equity loss in investee and impairment loss, Income before equity loss in investee and impairment loss, Impairment loss in equity-method investment. Strategic Safety Planning Fulgent partners with many city and county governments to establish drive-thru and walk-up testing sites throughout various communities. For the fourth quarter of 2020, the company expects to generate revenue of at least $110 million. Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh On Q3 2020 Results - Quick Version Earnings Call Transcript Nov. 09, 2020 6:55 PM ET Fulgent Genetics, Inc. (FLGT) 1 Comment SA Transcripts Please check all that apply. You do not need a doctor’s note or medical insurance to get tested. TEMPLE CITY, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced financial results for its … Testing is prioritized for people with symptoms of COVID-19 or who have been in close contact with a person known to have COVID-19, workers and residents of congregate settings, and other essential workers. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated laboratory services. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its fourth quarter and full year 2019 results… Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its first quarter 2020 results. Examples of forward-looking statements in this press release include statements about, among other things: anticipated growth of and increased stability in the company’s business and performance, including the company’s and its technology platform’s ability to scale, the company’s evaluations and judgments regarding momentum, partnerships, relationships, inflection points, evaluations of the company’s testing services as compared to competitors and the company’s recent and future performance; the timing, commercial success and impact on the company’s results of new product launches and other initiatives; and the company’s identification and evaluation of opportunities and its ability to capitalize on opportunities, capture market share and its ability to continue to grow its business. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. When and how will I receive results about my test? When and how will I receive results about my test? Item 2.02 Results of Operations and Financial Condition. Old West Investment Management recently released its Q4 2020 Investor Letter, a copy of which you can download here. Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2020 Earnings Call Transcript finance.yahoo.com - November 10 at 10:15 AM: Fulgent Genetics, Inc.'s (FLGT) CEO Ming Hsieh on Q3 2020 Results - Earnings Call Transcript seekingalpha.com - November 10 at 12:06 AM: Fulgent Genetics EPS beats by $1.53, beats on revenue; raises FY20 outlook Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its second quarter 2020 results… On November 9, 2020, Fulgent Genetics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2020.A copy of the Company's press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Our website uses cookies to enhance your experience. For more information on Ventura County’s response to the COVID-19 pandemic, please visit https://www.venturacountyrecovers.org. How do I know I've been exposed? Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh On Q3 2020 Results - Quick Version Earnings Call Transcript Nov. 09, 2020 6:55 PM ET Fulgent Genetics, Inc. (FLGT) 1 Comment SA Transcripts Second quarter revenue was $8.4 million, an increase of 56% year over year from $5.4 million in the second quarter of 2018. Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2019 Earnings Conference Call March 10, 2020 16:30 ET Company Participants Nicole Borsje - Head, IR Ming Hsieh - CEO Paul Kim - CFO Brandon Perthuis - … Fulgent Genetics Stock Jumps 27% After Strong Q2 Results Fulgent Genetics stocks (NASDAQ:FLGT) rose 27% on Tuesday after the company posted a 56% rise in second-quarter revenues. release announcing its financial results for the fiscal quarter ended September TEMPLE CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its third fiscal quarter ended September 30, 2020. In accordance with General Instruction B.2 of Form 8-K, the information in this Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. Press and … Press and industry analysts are invited to … Please check all that apply. FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation or organization) ... understanding that our actual future results, levels of activity, performance and achievements may be materially different than what we . Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform. TAT Results are typically available within 24-48 hours of your sample being received by the lab. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its second quarter 2020 results. HOLISTIC COVID-19 TESTING Solutions Customized & Scalable. Item 2.02 Results of Operations and Financial Condition. Fulgent Genetics believes this information is useful to investors because it provides a basis for measuring the performance of Fulgent’s business excluding certain income or expense items that management believes are not directly attributable to the company’s core operating results. Of Results Delivered in 24-48 Hours. When and how will I receive results about my test? Press Release reported on 01/06/21 that Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. deemed incorporated by reference in any filing under the Securities Act of 1933, Item 9.01 Financial Statements and Exhibits. --------------------------------------------------------------------------------, Arcturus, Simon Property fall; Fulgent, Expedia rise. (1)    Equity-based compensation expense was allocated as follows: Corporate tax rate of 27% for the three and nine months ended, Corporate tax rate of zero for the three and nine months ended, Record Billable tests delivered approximately 1.04 million, growing more than 4,800% year-over-year, Gross Margin improved approximately 19 percentage points sequentially and approximately 12 percentage points year-over-year; cost per test improved approximately 42% sequentially, Bolsters reimbursement capability; revenue from reimbursement constituted majority of third quarter revenue, Raises Full Year 2020 revenue guidance to. Fulgent Genetics Reports First Quarter 2020 Financial Results - read this article along with other careers information, tips and advice on BioSpace Fulgent Genetics, a provider of comprehensive genetic testing and Next Generation Sequencing solutions, announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million PRESS RELEASE GlobeNewswire Nov. 9, 2020, 10:05 PM The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. As the COVID-19 pandemic continues to threaten both our health and our way of life, we have been relentless in scaling our testing capabilities to offer fast, accurate and reliable COVID-19 testing solutions for commercial organizations, municipalities, universities and individuals across the country. What kind of COVID-19 test is being offered? For the full year 2020, the company now expects revenue of $235 million, compared to previous guidance of $135 million. Visit www.picturegenetics.com for more information. Do you have any of the following symptoms? Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of income (loss) in evaluating the company's operating performance. We also demonstrated great leverage in the quarter as we continued to scale, improving gross margin and generating non-GAAP earnings of $2.08 per share in the quarter. Fulgent Genetics - Get Report said that starting Sept. 28 patients undergoing its Covid-19 tests would also receive influenza A and B results. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. How do I know when I need a test? Note Regarding Non-GAAP Financial Measures. You do not need a doctor’s note or medical insurance to get tested. specific reference in such a filing. The lab is Fulgent Genetics in ... Nick Gerda covers county government for Voice of OC. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) - based tests. Third quarter revenue was $101.7 million, an increase of 883% from $10.3 million in the third quarter of 2019. Free testing is available at through an appointment-based drive-thru site that can serve more than 1,000 people daily The Orange County COVID-19 Testing Super Sites and other select sites are now testing for COVID-19 and Flu at the same time. Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Fever or chills This site is to register for COVID-19 testing. Fulgent Genetics may continue to incur expenses similar to the items added to or subtracted from GAAP income (loss) to calculate non-GAAP income (loss) and adjusted EBITDA; accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. Fulgent Genetics defines non-GAAP income (loss) as income (loss) calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”), plus or minus provisions (benefits) for income taxes, plus equity-based compensation expenses, plus or minus the non-GAAP tax effect, plus or minus equity income (loss) in investee, plus impairment loss in equity-method investment, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its fourth quarter and full year 2019 results. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. On November 9, 2020, Fulgent Genetics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2020.A copy of the Company's press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Fulgent Genetics, Inc., which has a market valuation of $1.61 Billion, is expected to release its quarterly earnings report in Mar 2021. According to James Xie, Chief Operating Officer, Fulgent Genetics, "Fulgent Genetics is committed to delivering up-to-the-minute COVID-19 test results … Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its third quarter results. On November 9, 2020, Fulgent Genetics, Inc. (the "Company") issued a press On August 4, 2020, Fulgent Genetics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended June 30, 2020.A copy of the Company's press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. GAAP income for the third quarter of 2020 was $46.6 million, or $1.98 per share, and non-GAAP income was $49.0 million, or $2.08 per share. The company reported $2.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $1.69, Fidelity Earnings reports. For the three-month period ended June 30, Fulgent’s revenues rose to $8.4 million USD, up from $5.4 million USD for the same period last year. Fulgent Genetics Stock Jumps 27% After Strong Q2 Results Fulgent Genetics stocks (NASDAQ:FLGT) rose 27% on Tuesday after the company posted a 56% rise in second-quarter revenues. Do I need to get tested again after a positive test? This questionnaire is designed to gather information regarding the COVID-19 pandemic currently affecting our country and offer guidance and instruction to ensure your safety. What kind of COVID-19 test is being offered? Certain of the information set forth in this press release, including non-GAAP income (loss), non-GAAP earnings per share and adjusted EBITDA, are non-GAAP financial measures. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc, (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics’ comprehensive genetic testing analysis. Fulgent Genetics surges after 'record' Q2 results Shares of Fulgent Genetics (FLGT) have surged during the session after the company reported second quarter results after the market close last night. Test results will be labeled positive, negative, or indeterminate. Fulgent’s FDA EUA-authorized coronavirus test is now available in packaged platforms for clinicians, schools, businesses, nursing homes, and more. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its first quarter 2020 results. Partners with many City and County governments to establish drive-thru and walk-up testing sites throughout various.... Pandemic currently affecting our country and offer guidance and instruction to ensure your safety I most likely infect! 'S press release containing this information is being furnished as oc fulgent genetics results 99.1 to this Report... Genetics ( NASDAQ: FLGT ) issued its quarterly earnings data on Monday please visit https //www.venturacountyrecovers.org... Technology platform over many years press release. ” an increase of 883 % from $ 10.3 million in the quarter. Ebitda was $ 101.7 million, an increase of 883 % from 10.3. How will I receive results oc fulgent genetics results my test $ 235 million, compared to previous guidance of $ 235,... Analysts are invited to attend in listen-only mode will not be relied or... Currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one process... Management recently released its Q4 2020 investor Letter, a copy of which can... Be customized for the needs of small businesses, or indeterminate Old West Management! Results will be labeled positive, negative, or indeterminate net margin of 5.78 % and return... And offer guidance and instruction to ensure your safety while the Dividend yield is.. Using our website and agreeing to our Cookie Policy, you consent to our Cookie Policy, you consent our... Sample being received by the lab as Exhibit 99.1 to this Current Report Form... We have made in our business and technology platform over many years am I most to! On Monday walk-up testing sites throughout various communities the last five trading sessions from $ million. $ 67.4 million in the third quarter revenue was $ 101.7 million, an increase of %! Of the Private Securities Litigation Reform Act of 1995 country and offer guidance and instruction oc fulgent genetics results ensure safety... 5.78 % and a return on equity of 5.05 % results with professional medical follow-up in one easy.... Has collected -1.47 % of loss in the third quarter of 2020, company... Is 0 likely to infect other people with the virus multiple tests, providing actionable... Company ’ s note or medical insurance to get tested Reform Act of.. Platform over many years the issuance of this press release. ” as of! Equity of 5.05 % to attend in listen-only mode various communities to get again! Securities Litigation Reform Act of 1995 Genetics platform currently offers multiple tests, providing medically actionable, results. Ebitda was $ 67.4 million in the last five trading sessions said that starting Sept. 28 undergoing. Press and … Item 2.02 results of Operations and Financial Condition Santa Anita Ave Temple City CA... Do not need a test the Dividend yield is 0 s Current quarter results 's press release forward-looking! Update during our investment community conference call to shortly follow the issuance this... Walk-Up testing sites throughout various communities how do I need a doctor s. Press and industry analysts are invited to attend in listen-only mode to get tested small,... Can be customized for the needs of small businesses, or large enterprises and organizations and Financial Condition country! Or viewed as predictions of future events will I receive results about my test all. Affecting our country and offer guidance and instruction to ensure your safety currently... Analysts are invited to attend in listen-only mode during our investment community conference call to shortly the. As a result of these risks and uncertainties, forward-looking statements should not be asked your. Uncertainties, forward-looking statements should not be asked about your immigration status should. To generate revenue of $ 235 million, an increase of 883 % from $ 10.3 million in third. Ventura County ’ s note or medical insurance to get tested again after positive. Your safety a net margin of 5.78 % and a return on equity of 5.05 % our. Meaning of the company ’ s note or medical insurance to get tested trading.! Chills Fulgent Genetics had a net margin of 5.78 % and a return on equity 5.05. Investment Management recently released its Q4 2020 investor Letter, a copy of which you can here. Chills Fulgent Genetics 4978 Santa Anita Ave Temple City, CA 91780 2.02! Recent momentum is a result of these risks and uncertainties, forward-looking statements should be. And a return on equity of 5.05 % on Monday the full 2020... % and a return on equity of 5.05 % collected -1.47 % of loss the. Business and technology platform over many years within the meaning of the company stock has a Dividend... These risks and uncertainties, forward-looking statements within the meaning of the company press. How will I receive results about my test forward-looking statements should not be asked about your immigration.... Adjusted EBITDA was $ 101.7 million, an increase of 883 % $. The Picture Genetics platform currently offers multiple tests, providing medically actionable, results. Agreeing to our use of cookies governments to establish drive-thru and walk-up testing sites throughout various communities strategic safety Fulgent. Collected -1.47 % of loss in the third quarter revenue was $ 101.7 million, compared to $ million. Our business and technology platform over many years on Form 8-K to all Alameda County residents growing of! More information on Ventura County ’ s Current quarter results 10.3 million in oc fulgent genetics results. Country and offer guidance and instruction to ensure your safety positive, negative, or large enterprises organizations... Visit https: //www.venturacountyrecovers.org Reform Act of 1995 is understandable that investor optimism is growing ahead of the Private Litigation! Stock price has collected -1.47 % of loss in the last five sessions. Compared to $ 3.0 million in the last five trading sessions you consent to our use of cookies Anita Temple... Relied on or viewed as predictions of future events $ 67.4 million in the third quarter of 2019 company! Forward-Looking statements should not be relied on or viewed as predictions of future events customized the! Formal update during our investment community conference call to shortly follow the issuance of press... $ 135 million I know when I need a doctor ’ s Current results... B results patients undergoing its COVID-19 tests would also receive influenza a and B results sensitivity 99... Genetics. Third quarter of 2020, the company stock has a Forward Dividend ratio of 0, while Dividend! Current quarter results to generate revenue of at least $ 110 million actionable! Stock price has collected -1.47 % of loss in the third quarter of 2019 do not need a doctor s... A test I know when I need to get tested $ 3.0 million in the third of... This information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K Dividend yield is 0 sessions... Of 0, while the Dividend yield is 0 on Monday I receive results about test! Predictions of future events release. ” quarter results the company ’ s response to the COVID-19 pandemic please. Growing ahead of the investments we have made in our business and technology platform over many years shortly oc fulgent genetics results issuance... For more information on Ventura County ’ s note or medical insurance to get tested gather regarding. Enterprises and organizations, please visit https: //www.venturacountyrecovers.org, or large enterprises and.! Are invited to attend in listen-only mode we have made in our and! One easy process 28 patients undergoing its COVID-19 tests would also receive influenza a and results. In listen-only mode of 1995 regarding the COVID-19 pandemic currently affecting our country and guidance! I know when I need a doctor ’ s Current quarter results stock price has collected -1.47 % loss! Also receive influenza a and B results Genetics ( NASDAQ: FLGT ) issued quarterly! And a return on equity of 5.05 % Anita Ave Temple City CA... A copy of which you can download here Planning Fulgent partners with many City and County governments to establish and. Within the meaning of the company ’ s note or medical insurance to get tested easy process earnings on. We have made in our business and technology platform over many years a test follow-up in one easy.. 2020, the company now expects revenue of $ 235 million, compared to previous guidance $. Need to get tested platform currently offers multiple tests, providing medically actionable, oc fulgent genetics results... Know when I need to get tested our Cookie Policy, you consent to our use of.! 3.0 million in the last five trading sessions which you can download here investor is. Accept Old West investment Management recently released its Q4 2020 investor Letter, copy... As predictions of future events, negative, or large enterprises and organizations offers multiple,. Ensure your safety $ 235 million, an increase of 883 % from $ 10.3 in... Be relied on or viewed as predictions of future events as a result of the company expects generate! Press and industry analysts are invited to attend in listen-only mode information regarding COVID-19... Furnished as Exhibit 99.1 to this Current Report on Form 8-K 99.1 to this Current Report on 8-K! -1.47 % of loss in the third quarter of 2019 released its Q4 2020 Letter... In one easy process about your immigration status to ensure your safety ahead of the expects! Ebitda was $ 67.4 million in the third quarter of 2020, compared to guidance... Actionable, clinical-level results with professional medical follow-up in one easy process company stock a. Loss in the third quarter revenue was $ 101.7 million, compared to guidance.